Treatment and prognosis of stage I follicular lymphoma in the modern era–does PET matter?

Ohad S. Bentur, Ronit Gurion, Anat Gafter-Gvili, Moshe Gatt, Lev Shvidel, Netanel A. Horowitz, Ron Ram, Yair Herishanu, Nadav Sarid, Ora Paltiel, Chezi Ganzel, Natalia Kreiniz, Najib Dally, Odit Gutwein, Pia Raanani, Irit Avivi, Chava Perry*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. Patients with stage I disease are usually treated with radiotherapy (RT). In previous studies, mostly from the pre positron emission tomography–computed tomography (PET-CT) era, the 5 year progression-free survival (PFS) and overall survival (OS) rates of stage I disease were 60–80% and 80–93%, respectively. This study retrospectively evaluated the outcome of stage I FL which was treated with involved field RT in the PET-CT era between 2002 and 2015. Ninety-one patients were enrolled. Five year PFS and OS rates were 73% and 97%, respectively. Relapse occurred in 19 (21%) patients, 74% occurring outside the radiation field. In conclusion, PET-CT staging of clinical stage I FL may contribute to the improved prognosis in patients treated with RT compared to historical cohorts, possibly due to better identification of “genuine” stage I disease.

Original languageAmerican English
Pages (from-to)1163-1171
Number of pages9
JournalLeukemia and Lymphoma
Issue number5
StatePublished - 4 May 2018

Bibliographical note

Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.


  • Follicular lymphoma
  • immunotherapy
  • positron emission tomography
  • radiotherapy
  • rituximab


Dive into the research topics of 'Treatment and prognosis of stage I follicular lymphoma in the modern era–does PET matter?'. Together they form a unique fingerprint.

Cite this